# US 2004/0018973 A1 · Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018973 A1
- Document ID: US20040018973A1
- Status: Published application
- Kind: A1
- Application number: 10/350,367
- Filed: 2003-01-24
- Published: 2004-01-29
- Earliest claimed: 2002-01-25
- Assignees: University of Pittsburgh
- Inventors: Anthony J. Bauer; Gisela Bruenagel; Robert H. Getzenberg; Robert E. Schoen
- Web page: https://patentgrep.com/patent/US20040018973A1

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/47: from mammals
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.

## Claims

### Claim 1

A purified protein which is present in cancerous colon cells but absent or reduced in amount in normal colonic epithelial cells, said protein selected from the group consisting of:
a) CC2 having a molecular weight of about 56 kD and a pI of about 6.22;
b) CC3 having a molecular weight of about 43 kD and a pI of about 6.3;
c) CC4 having a molecular weight of about 43 kD and a pI of about 6.2;
d) CC5 having a molecular weight of about 42 kD and a pI of about 6.2;
e) CC6a having a molecular weight of about 20 kD and a pI of about 6.9;
f) CC6b having a molecular weight of about 20 kD and a pI of about 6.8.
g) L1 having a molecular weight of about 50 kD and a pI of about 6.01;
h) L2 having a molecular weight of about 20 kD and a pI of about 5.73; and
i) L5 having a molecular weight of about 19 kD and a pI of about 5.88.

### Claim 2 (depends on 1)

The purified protein of claim 1 wherein said protein is CC2.

### Claim 3 (depends on 1)

The purified protein of claim 1 wherein said protein is CC3.

### Claim 4 (depends on 1)

The purified protein of claim 1 wherein said protein is CC4.

### Claim 5 (depends on 1)

The purified protein of claim 1 wherein said protein is CC5.

### Claim 6 (depends on 1)

The purified protein of claim 1 wherein said protein is CC6a.

### Claim 7 (depends on 1)

The purified protein of claim 1 wherein said protein is CC6b.

### Claim 8 (depends on 1)

The purified protein of claim 1 wherein said protein is L1.

### Claim 9 (depends on 1)

The purified protein of claim 1 wherein said protein is L2.

### Claim 10 (depends on 1)

The purified protein of claim 1 wherein said protein is L5.

### Claim 11 (depends on 1)

The purified protein of claim 1 wherein said protein is more detectable in colon cancer metastasis to liver than in normal liver tissue.

### Claim 12 (depends on 11)

The purified protein of claim 11 wherein said protein is L1, L2 or L3.

### Claim 13 (depends on 2)

The purified protein of claim 2 wherein CC2 comprises an amino acid sequence shown as SEQ ID NO: 14, 15, 16, 17 or 23.

### Claim 14 (depends on 3)

The purified protein of claim 3 wherein CC3 comprises an amino acid sequence shown as SEQ ID NO: 24-26.

### Claim 15 (depends on 4)

The purified protein of claim 4 wherein CC4 comprises an amino acid sequence shown as SEQ ID NO: 27-29.

### Claim 16 (depends on 5)

The purified protein of claim 5 wherein CC6a comprises an amino acid sequence shown as SEQ ID NO: 18-20.

### Claim 17 (depends on 6)

The purified protein of claim 6 wherein CC6b comprises an amino acid sequence shown as SEQ ID NO: 21.

### Claim 18 (depends on 9)

The purified protein of claim 9 wherein L2 comprises an amino acid sequence shown as SEQ ID NO: 30-32.

### Claim 19 (depends on 10)

The purified protein of claim 10 wherein L5 comprises an amino acid sequence shown as SEQ ID NO: 33-36.

### Claim 20 (depends on 1)

The purified protein of claim 1, wherein said protein is present in a nuclear matrix preparation.

### Claim 21 (depends on 1)

A binding partner specific for the purified protein of claim 1.

### Claim 22 (depends on 21)

The purified protein of claim 21, wherein said binding partner is a monoclonal antibody.

### Claim 23 (depends on 21)

The purified protein of claim 21, wherein said binding partner is a polyclonal antibody.

### Claim 24

A purified protein which is present in normal epithelial colonic cells but absent or reduced in amount cancerous colon cells, said protein selected from the group consisting of:
a) N1 having a molecular weight of about 40 kD and a pI of about 5.5;
b) N2 having a molecular weight of about 30 kD and a pI of about 5.94;
c) N3 having a molecular weight of about 30 kD and a pI of about 5.88;
d) N4 having a molecular weight of about 30 kD and a pI of about 5.80;
e) N5 having a molecular weight of about 30 kD and a pI of about 5.73; and
f) N6 having a molecular weight of about 18 kD and a pI of about 6.6.

### Claim 25 (depends on 24)

The purified protein of claim 24 wherein said protein is N1.

### Claim 26 (depends on 24)

The purified protein of claim 24 wherein said protein is N2.

### Claim 27 (depends on 24)

The purified protein of claim 24 wherein said protein is N3.

### Claim 28 (depends on 24)

The purified protein of claim 24 wherein said protein is N4.

### Claim 29 (depends on 24)

The purified protein of claim 24 wherein said protein is N5.

### Claim 30 (depends on 24)

The purified protein of claim 24 wherein said protein is N5.

### Claim 31 (depends on 24)

The purified protein of claim 24, wherein said protein is present in a nuclear matrix preparation.

### Claim 32 (depends on 24)

A binding partner specific for the purified protein of claim 24.

### Claim 33 (depends on 32)

The purified protein of claim 32, wherein said binding partner is a monoclonal antibody.

### Claim 34 (depends on 32)

The purified protein of claim 32, wherein said binding partner is a polyclonal antibody.

### Claim 35

A purified protein which is present in primary colon cancer cells and liver metastasis derived therefrom and is useful as a cancer diagnostic marker, said protein selected from the group consisting of:
a) L3 having a molecular weight of about 18 kD and a pI of about 6.09; and
b) L4 having a molecular weight of about 18 kD and a pI of about 6.00.

### Claim 36 (depends on 35)

The purified protein of claim 35, wherein said protein is L3.

### Claim 37 (depends on 35)

The purified protein of claim 35, wherein said protein is L4.

### Claim 38 (depends on 35)

The purified protein of claim 35, wherein said protein is present in a nuclear matrix preparation.

### Claim 39 (depends on 35)

A binding partner specific for the purified protein of claim 35.

### Claim 40 (depends on 39)

The purified protein of claim 39 wherein said binding partner is a monoclonal antibody.

### Claim 41 (depends on 39)

The purified protein of claim 39, wherein said binding partner is a polyclonal antibody.

### Claim 42 (depends on 1)

A method of producing polyclonal antibodies that differentiate between cancerous and normal colonic epithelial cells comprising immunizing an animal with the protein of claim 1 and recovering said antibodies.

### Claim 43 (depends on 24)

A method of producing polyclonal antibodies that differentiate between cancerous and normal colonic epithelial cells comprising immunizing an animal with the protein of claim 24 and recovering said antibodies.

### Claim 44 (depends on 35)

A method of producing polyclonal antibodies that differentiate between colon cancer metastases to liver and normal liver epithelial cells comprising immunizing an animal with the protein of claim 35 and recovering said antibodies.

### Claim 45 (depends on 1)

A method~of producing a monoclonal antibody that differentiates between cancerous and normal colonic epithelial cells comprising immunizing an animal with the protein of claim 1, removing B cells from the immunized animal and: i) immortalizing and isolating said B cells that produce an antibody specific for said protein or ii) obtaining nucleic acid encoding antibody heavy and light chains from the cells, transforming, transfecting or transducing host cells with one or more expression vectors containing the nucleic acid such that the host cells produce antibody encoded by said nucleic acid, and selecting host cells produce an antibody specific for the protein.

### Claim 46 (depends on 24)

A method of producing a monoclonal antibody that differentiates between cancerous and normal colonic epithelial cells comprising immunizing an animal with the protein of claim 24, removing B cells from the immunized animal and: i) immortalizing and isolating said B cells that produce an antibody specific for said protein or ii) obtaining nucleic acid encoding antibody heavy and light chains from the cells, transforming, transfecting or transducing host cells with one or more expression vectors containing the nucleic acid such that the host cells produce antibody encoded by said nucleic acid, and selecting host cells produce an antibody specific for the protein.

### Claim 47 (depends on 35)

A method of producing a monoclonal antibody that differentiates between colon cancer metastases to liver and normal liver epithelial cells comprising immunizing an animal with the protein of claim 35, removing B cells from the immunized animal and: i) immortalizing and isolating said B cells that produce an antibody specific for said protein or ii) obtaining nucleic acid encoding antibody heavy and light chains from the cells, transforming, transfecting or transducing host cells with one or more expression vectors containing the nucleic acid such that the host cells produce antibody encoded by said nucleic acid, and selecting host cells produce an antibody specific for the protein.

### Claim 48

A method of diagnosing a proliferative disorder of the colon in a patient, said method comprising: analyzing tissue, stool or body fluid from the patient for the presence of at least one protein that is present in cancerous colonic cells but absent or reduced in amount in normal colonic epithelial cells, or present in normal colonic epithelial cells but absent or reduced in amount in cancerous colonic cells, wherein said protein is selected from the group consisting of:
a) CC2 having a molecular weight of about 56 kD and a pI of about 6.22;
b) CC3 having a molecular weight of about 43 kD and a pI of about 6.3;
c) CC4 having a molecular weight of about 43 kD and a pI of about 6.2;
d) CC5 having a molecular weight of about 42 kD and a pI of about 6.2;
e) CC6a having a molecular weight of about 20 kD and a pI of about 6.9;
f) CC6b having a molecular weight of about 20 kD and a pI of about 6.8.
g) L1 having a molecular weight of about 50 kD and a pI of about 6.01;
h) L2 having a molecular weight of about 20 kD and a pI of about 5.73;
i) L5 having a molecular weight of about 19 kD and a pI of about 5.88;
j) N1 having a molecular weight of about 40 kD and a pI of about 5.5;
k) N2 having a molecular weight of about 30 kD and a pI of about 5.94;
l) N3 having a molecular weight of about 30 kD and a pI of about 5.88;
m) N4 having a molecular weight of about 30 kD and a pI of about 5.80;
n) N5 having a molecular weight of about 30 kD and a pI of about 5.73; and
o) N6 having a molecular weight of about 18 kD and a pI of about 6.6.

### Claim 49 (depends on 48)

The method of claim 48 wherein the presence of said at least one protein is detected by 2 dimensional gel electrophoresis.

### Claim 50 (depends on 48)

The method of claim 48 wherein the presence of said at least one protein is detected with a binding partner specific for the protein.

### Claim 51 (depends on 50)

The method of claim 50 wherein said binding partner is a monoclonal or polyclonal antibody.

### Claim 52 (depends on 48)

The method of claim 48 wherein the presence of said at least one protein is determined by detecting mRNA encoding the protein through hybridization with a nucleic acid.

### Claim 53 (depends on 48)

The method of claim 48, wherein said purified protein is present in a nuclear matrix preparation.

### Claim 54

A method of diagnosing colon cancer in a patient, said method comprising: analyzing tissue, stool or body fluid from the patient for the presence of calreticulin.

### Claim 55 (depends on 54)

The method of claim 54 wherein said detection is by two-dimensional gel electrophoresis.

### Claim 56 (depends on 54)

The method of claim 54 wherein calreticulin is detected by a specific binding partner.

### Claim 57 (depends on 56)

The method of claim 56 wherein the specific binding partner is a monoclonal or polyclonal antibody.

### Claim 58 (depends on 56)

The method of claim 56 wherein calreticulin is detected by hybridizing with a nucleic acid for calreticulin.

### Claim 59 (depends on 54)

The method of claim 54 wherein tissue is analyzed.

### Claim 60 (depends on 59)

The method of claim 59 where said tissue is a nuclear matrix preparation.

### Claim 61 (depends on 54)

The method of claim 54 wherein said proliferative disorder is colorectal carcinoma.

### Claim 62 (depends on 54)

The method of claim 54 wherein said proliferative disorder is colonic adenoma.

### Claim 63 (depends on 62)

The method of claim 62 wherein said proteins are CC3, CC4 or CC5.

### Claim 64

A method of evaluating colonic adenomas for potential to become malignant, said method comprising: analyzing the adenoma for the presence of at least one protein that is present in cancerous colonic cells but absent or reduced in amount in normal colonic epithelial cells, or present in normal colonic epithelial cells but absent or reduced in amount in cancerous colonic cells, wherein said protein is selected from the group consisting of:
a) CC2 having a molecular weight of about 56 kD and a pI of about 6.22;
b) CC3 having a molecular weight of about 43 kD and a pI of about 6.3;
c) CC4 having a molecular weight of about 43 kD and a pI of about 6.2;
d) CC5 having a molecular weight of about 42 kD and a pI of about 6.2;
e) CC6a having a molecular weight of about 20 kD and a pI of about 6.9;
f) CC6b having a molecular weight of about 20 kD and a pI of about 6.8.
g) L1 having a molecular weight of about 50 kD and a pI of about 6.01;
h) L2 having a molecular weight of about 20 kD and a pI of about 5.73;
i) L5 having a molecular weight of about 19 kD and a pI of about 5.88;
j) N1 having a molecular weight of about 40 kD and a pI of about 5.5;
k) N2 having a molecular weight of about 30 kD and a pI of about 5.94;
l) N3 having a molecular weight of about, 30 kD and a pI of about 5.88;
m) N4 having a molecular weight of about 30 kD and a pI of about 5.80;
n) N5 having a molecular weight of about 30 kD and a pI of about 5.73; and
o) N6 having a molecular weight of about 18 kD and a pI of about 6.6; and
wherein detection of said proteins indicates an increased potential to become malignant.

### Claim 65 (depends on 64)

The method of claim 64 wherein the presence of said at least one protein is detected by 2 dimensional gel electrophoresis.

### Claim 66 (depends on 64)

The method of claim 64 wherein the presence of said at least one protein is detected with a binding partner specific for the protein.

### Claim 67 (depends on 66)

The method of claim 66 wherein said binding partner is a monoclonal or polyclonal antibody.

### Claim 68 (depends on 64)

The method of claim 64 wherein the presence of said at least one protein is determined by detecting mRNA encoding the protein through hybridization with a nucleic acid.

### Claim 69 (depends on 64)

The method of claim 64 wherein said proteins are CC3, CC4 and CC5.

### Claim 70

A method of diagnosing colon cancer to liver metastasis in a patient, said method comprising: analyzing a sample of liver for the presence of at least one protein, wherein said protein is selected from the group consisting of:
a) L1 having a molecular weight of about 50 kD and a pI of about 6.01;
b) L2 having a molecular weight of about 20 kD and a pI of about 5.73;
c) L3 having a molecular weight of about 17 kD and a pI of about 6.09;
d) L4 having a molecular weight of about 17 kD and a pI of about 6.00; and
e) L5 having a molecular weight of about 19 kD and a pI of about 5.88.

### Claim 71 (depends on 70)

The method of claim 70, wherein the presence of said at least one protein is detected by high resolution, two-dimensional gel electrophoresis.

### Claim 72 (depends on 70)

The method of claim 70, wherein the presence of said at least one protein is detected with a binding partner specific for the protein.

### Claim 73 (depends on 72)

The method of claim 72, wherein said binding partner is a monoclonal or polyclonal antibody.

### Claim 74 (depends on 72)

The method of claim 72, wherein said protein is detected by hybridizing with a nucleic acid for calreticulin.

### Claim 75 (depends on 1)

A diagnostic assay kit for determining the presence of the protein of claim 1, comprising at least one binding partner which is capable of specifically binding with the protein.

### Claim 76 (depends on 75)

The diagnostic assay kit of claim 75, wherein said binding partner is immobilized on a solid support.

### Claim 77 (depends on 75)

The diagnostic assay kit of claim 75 wherein said binding partner is detectably labeled.

### Claim 78 (depends on 75)

The diagnostic assay kit of claim 75, wherein said binding partner is an antibody.
